Canadian Respiratory Journal

Canadian Respiratory Journal / 2004 / Article

Open Access

Volume 11 |Article ID 534612 | https://doi.org/10.1155/2004/534612

Sat Sharma, "Steroids and/or Cytotoxic Agents Should Be Used Early in the Management of Patients with IPF -- The Pro Argument", Canadian Respiratory Journal, vol. 11, Article ID 534612, 3 pages, 2004. https://doi.org/10.1155/2004/534612

Steroids and/or Cytotoxic Agents Should Be Used Early in the Management of Patients with IPF -- The Pro Argument

Abstract

Idiopathic interstitial pneumonias comprise a heterogenous group of acute and chronic respiratory conditions. Katzenstein and Myers (1) classified these disorders according to several pathologically distinct categories: usual interstitial pneumonitis (UIP), desquamative interstitial pneumonitis ? respiratory bronchiolitis interstitial lung disease, acute interstitial pneumonitis, nonspecific interstitial pneumonitis and cryptogenic organizing pneumonitis or bronchiolitis obliterans organizing pneumonia (1). These disorders present with similar clinical features of shortness of breath, diffuse pulmonary infiltrates on chest radiograph, and histologically, a varying combination of inflammation and fibrosis. However, the natural history and response to therapy differs substantially, as some categories have more favourable prognoses than others (2). Idiopathic pulmonary fibrosis (IPF) or fibrosing alveolitis is the clinical terminology for a specific interstitial pneumonia for which the pathological process is UIP. A disorder of unknown etiology, IPF is the most common and most lethal of all interstitial pneumonias.

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views51
Downloads239
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.